see
editori
commentari
branch
falsey
page
background
respiratori
tract
infect
frequent
caus
hospit
initi
empir
antimicrobi
therapi
test
broad
panel
respiratori
virus
advoc
use
tool
antibiot
stewardship
conduct
prospect
observ
studi
assess
impact
rapid
viral
test
result
antimicrobi
prescript
clinic
outcom
among
hospit
adult
method
eight
hundr
patient
admit
respiratori
symptom
test
respiratori
panel
rvp
consecut
winter
montreal
canada
primari
outcom
measur
chang
antimicrobi
prescript
ie
deescal
empir
antimicrobi
therapi
commenc
new
antimicrobi
therapi
rvp
result
avail
clinic
outcom
also
assess
result
influenza
viru
identifi
individu
studi
popul
virus
identifi
influenza
viru
posit
associ
shorter
durat
hospit
appropri
antivir
manag
antibiot
manag
significantli
correl
radiograph
suspicion
pneumonia
less
result
rvp
posit
virus
influenza
viru
correl
significantli
differ
outcom
conclus
physician
respond
result
test
influenza
viru
manag
hospit
adult
patient
respond
less
test
result
virus
data
inform
design
stewardship
intervent
select
viral
test
panel
hospit
patient
acut
respiratori
tract
infect
common
caus
infectionrel
death
worldwid
differenti
bacteri
viral
infect
clinic
challeng
frequent
lead
empir
antibacteri
therapi
turn
contribut
burden
antimicrobi
resist
recent
antimicrobi
stewardship
implement
guidelin
rapid
test
broad
panel
respiratori
virus
advoc
import
intervent
reduc
use
inappropri
antibiot
respiratori
tract
infect
weak
recommendationpoor
qualiti
evid
nucleic
acid
amplificationbas
test
gold
standard
laboratori
confirm
respiratori
virus
howev
costli
especi
target
broad
array
virus
absenc
solid
outcom
studi
specif
assess
impact
antimicrobi
use
hospit
resourc
util
institut
face
difficult
decis
choic
test
patient
like
benefit
test
studi
conduct
among
pediatr
popul
shown
rapid
viral
test
gener
contribut
reduc
antibiot
use
among
adult
patient
yield
conflict
result
small
reduct
antibiot
use
shorter
durat
hospit
lower
overal
cost
note
studi
test
result
commun
physician
rapidli
howev
limit
small
sampl
size
comparison
histor
control
fact
includ
outpatientsmak
difficult
extrapol
result
acut
care
hospit
set
introduc
laboratorydevelop
realtim
polymeras
chain
reactionbas
viru
panel
rvp
institut
rvp
overal
posit
rate
calcul
use
data
season
patient
around
turnaround
time
hour
quickli
adopt
clinician
use
tool
analyz
patient
present
acut
respiratori
syndrom
object
studi
prospect
evalu
whether
rapid
viral
test
result
lead
chang
antimicrobi
prescript
among
adult
hospit
respiratori
tract
infect
whether
result
help
predict
import
clinic
outcom
data
studi
better
inform
role
respiratori
viru
test
within
antibiot
stewardship
program
mcgill
univers
health
centr
muhc
tertiari
care
center
downtown
montreal
canada
hospit
campus
adult
patient
patient
present
respiratori
symptom
test
rvp
discret
treat
team
staff
remind
everi
winter
season
via
memo
post
notic
import
respiratori
viru
test
particularli
patient
requir
admiss
appropri
infect
control
measur
need
implement
studi
perform
secondari
analys
data
collect
context
surveil
seriou
influenza
ill
vaccin
effect
sponsor
seriou
outcom
surveil
network
public
health
agenc
canada
canadian
institut
health
research
influenza
research
network
receiv
ethic
approv
institut
review
board
muhc
prospect
identifi
potenti
studi
particip
laboratori
log
rvp
test
consecut
winter
novemberapril
crossreferenc
data
hospit
inform
system
screen
rvptest
patient
hospit
hour
potenti
enrol
elig
criteria
includ
acut
respiratori
tract
infect
ie
pneumonia
influenzalik
ill
exacerb
chronic
obstruct
pulmonari
diseas
copd
asthma
unexplain
sepsi
influenzalik
symptom
eg
fever
dyspnea
cough
sore
throat
myalgia
subject
exclud
test
respiratori
virus
day
onset
symptom
sinc
detect
viral
nucleic
acid
case
might
correl
activ
infect
infect
consid
acquir
hospit
reason
admiss
clearli
unrel
respiratori
tract
infect
train
clinic
research
monitor
extract
follow
data
medic
record
enrol
patient
age
sex
comorbid
frailti
score
patient
age
year
score
defin
scale
denot
fit
denot
termin
ill
radiograph
suspicion
physician
pneumonia
time
admiss
complic
eg
thromboembol
clostridium
difficil
infect
hospit
hospit
detail
includ
intens
care
unit
icu
admiss
antibiot
antivir
prescript
data
durat
hospit
death
studi
monitor
sought
inform
consent
interview
patient
detail
vaccin
healthcar
util
inform
context
vaccin
effect
studi
subject
provid
consent
exclud
vaccin
effect
analysi
current
studi
deidentifi
clinic
data
obtain
chart
review
analyz
princip
investig
review
data
extern
auditor
monitor
data
qualiti
yearli
nasopharyng
swab
specimen
collect
patient
treat
team
upon
order
physician
place
univers
transport
medium
sent
laboratori
day
test
panel
target
influenza
b
virus
respiratori
syncyti
viru
rsv
b
rhinovirusenteroviru
parainfluenza
viru
adenoviru
human
metapneumoviru
coronaviru
rvp
assay
develop
muhc
valid
lower
limit
detect
virus
compar
direct
fluoresc
antibodi
cultur
rvp
test
done
time
per
day
weekday
earli
morn
afternoon
even
overnight
run
time
per
day
weekend
depend
volum
specimen
minim
analyt
test
time
hour
turnaround
time
rang
hour
median
turnaround
time
specimen
collect
final
verif
hour
minut
hospit
laboratori
situat
hour
minut
second
hospit
situat
away
result
rvp
fax
ward
also
immedi
avail
electron
hospit
laboratori
inform
system
addit
avoid
delay
manag
treat
team
notifi
telephon
posit
test
result
label
preliminari
even
final
report
issu
analyz
antibiot
prescrib
presum
respiratori
tract
infect
unexplain
sepsi
ceftriaxon
doxycyclin
azithromycin
piperacillintazobactam
imipenem
meropenem
intraven
vancomycin
moxifloxacin
levofloxacin
per
institut
guidelin
empir
therapi
includ
antibiot
prescrib
infect
eg
cefazolin
oral
vancomycin
antivir
use
institut
treatment
influenza
oseltamivir
main
object
evalu
whether
rapid
avail
rvp
result
impact
antimicrobi
use
hospit
specif
evalu
whether
knowledg
rvp
result
led
chang
antimicrobi
prescript
defin
chang
treatment
first
distinguish
patient
treat
test
possibl
determin
precis
treat
physician
becam
awar
test
result
basi
turnaround
time
hour
made
assumpt
first
antimicrobi
prescrib
date
test
collect
day
start
test
among
chang
measur
term
discontinu
treatment
antimicrobi
day
test
eg
discontinu
antibiot
rvp
detect
viru
second
among
patient
treat
test
chang
measur
term
commenc
antimicrobi
treatment
day
test
eg
commenc
antivir
rvp
detect
influenza
viru
hypothes
posit
test
result
influenza
viru
would
associ
continu
commenc
antivir
treatment
detect
viru
rvp
would
result
greater
likelihood
discontinu
antibiot
particularli
patient
radiograph
suspicion
pneumonia
classifi
patient
accord
rvp
find
influenza
viru
posit
posit
virus
influenza
viru
hereaft
viru
posit
viru
neg
patient
test
posit
influenza
viru
anoth
viru
analyz
influenza
virusposit
group
compar
clinic
characterist
patient
calcul
differ
mean
continu
characterist
proport
categor
characterist
associ
confid
interv
ci
differ
proport
calcul
confid
interv
use
wilson
method
studi
impact
rvp
find
outcom
measur
stratifi
patient
whether
began
treatment
test
suspect
pneumonia
statu
among
patient
began
treatment
test
calcul
percentag
patient
discontinu
antimicrobi
treatment
categori
defin
rvp
result
likewis
categori
find
yield
rvp
calcul
percentag
patient
commenc
antimicrobi
treatment
test
result
antivir
antibiot
treatment
analyz
separ
adjust
confound
variabl
fit
cox
proport
hazard
model
main
outcom
measur
includ
rvp
find
age
charlson
index
comorbid
index
base
number
preexist
chronic
condit
present
admiss
valid
predict
mortal
longitudin
studi
suspicion
pneumonia
independ
variabl
patient
whose
antimicrobi
treatment
discontinu
death
hospit
discharg
treat
censor
patient
began
treatment
test
receiv
antivir
day
date
specimen
collect
analysi
rvp
therefor
would
complet
day
treatment
within
day
test
drop
model
analys
perform
use
sa
version
sa
institut
total
adult
patient
test
rvp
studi
period
screen
enrol
hospit
met
elig
criteria
therefor
includ
detail
analysi
figur
winter
studi
patient
influenza
virusposit
result
test
posit
influenza
viru
test
posit
influenza
b
viru
virusposit
result
virus
influenza
viru
detect
frequent
adenoviru
rsv
respect
tabl
two
virus
detect
patient
group
patient
influenza
viru
posit
viru
posit
viru
neg
compar
term
sex
distribut
age
charlson
index
total
patient
radiograph
suspicion
pneumonia
admiss
suspicion
pneumonia
least
patient
initi
treatment
prior
test
receiv
treatment
day
specimen
collect
respiratori
viru
panel
rvp
test
c
patient
treat
rvp
find
avail
start
treatment
day
specimen
collect
rvp
test
patient
treat
patient
start
end
treatment
prior
test
patient
receiv
antibiot
nonrespiratori
ill
death
group
patient
test
posit
rsv
test
posit
rhinoviru
total
patient
initi
antibiot
andor
antivir
test
tabl
suspicion
pneumonia
common
group
compar
treat
test
differ
ci
supplementari
tabl
clinic
outcom
death
icu
admiss
complic
similar
frequenc
among
influenza
posit
patient
without
radiograph
suspicion
pneumonia
oseltamivir
continu
tabl
censor
influenza
virusposit
patient
die
discharg
complet
day
oseltamivir
within
day
test
oseltamivir
discontinu
without
suspicion
pneumonia
renal
tabl
among
patient
initi
antibiot
test
laboratori
confirm
influenza
viru
infect
antibiot
discontinu
without
suspicion
pneumonia
tabl
antibiot
discontinu
signific
univari
analysi
ci
tabl
laboratori
confirm
anoth
viru
antibiot
discontinu
patient
without
suspicion
pneumonia
treatment
start
test
influenza
virusposit
result
led
start
oseltamivir
patient
without
suspicion
pneumonia
among
patient
suspicion
pneumonia
antibiot
prescrib
influenza
virusposit
group
virusposit
group
virusneg
group
tabl
result
multivari
cox
proport
hazard
model
appear
tabl
influenza
virusposit
test
result
significantli
correl
oseltamivir
use
influenza
virusposit
patient
receiv
antivir
test
time
like
ci
initi
oseltamivir
laboratori
confirm
influenza
viru
infect
compar
virusneg
patient
similarli
among
patient
receiv
antivir
test
influenza
virusposit
patient
time
like
antivir
discontinu
ci
compar
virusneg
patient
note
trend
discontinu
antibiot
influenza
virusposit
test
result
univari
analysi
radiograph
suspicion
pneumonia
admiss
correl
continu
antibiot
treatment
among
patient
treat
avail
test
result
commenc
antibiot
among
treat
avail
test
result
goal
assess
whether
rapid
test
broad
panel
virus
would
use
tool
antimicrobi
stewardship
effort
particularli
earli
manag
adult
requir
hospit
whether
viral
detect
lead
differ
clinic
outcom
hypothes
knowledg
influenza
viru
posit
would
lead
institut
appropri
antivir
deescal
antibiot
posit
virus
would
lead
cessat
oseltamivir
antibiot
patient
popul
consist
moder
vulner
frail
mostli
elderli
patient
alreadi
signific
risk
death
within
year
base
charlson
index
correspond
predict
mortal
rate
major
start
antimicrobi
therapi
presum
respiratori
tract
infect
upon
present
rvp
result
avail
consecut
winter
influenza
viru
detect
studi
patient
frequenc
significantli
higher
overal
rate
influenza
viru
detect
commun
base
result
laboratori
influenza
viru
detect
respiratori
virus
nasopharyng
specimen
includ
children
ambulatori
patient
studi
period
suggest
influenza
viru
major
caus
admiss
respiratori
tract
infect
among
adult
institut
one
studi
set
similar
quebec
canada
report
higher
rel
contribut
virus
influenza
viru
among
patient
contribut
variabl
year
year
account
infect
one
year
next
studi
nearli
half
virusposit
patient
radiograph
suspicion
lower
respiratori
tract
infect
major
requir
supplement
oxygen
therapi
suggest
virus
like
implic
lower
respiratori
tract
infect
copdasthma
exacerb
howev
posit
virus
influenza
viru
appear
import
determin
signific
clinic
outcom
durat
hospit
observ
data
suggest
earli
initi
oseltamivir
associ
improv
overal
outcom
fewer
influenzarel
complic
hospit
patient
data
confirm
clinician
use
rapidli
avail
result
influenza
viru
test
guid
appropri
appropri
antivir
therapi
rvp
detect
influenza
viru
physician
time
like
continu
oseltamivir
start
empir
time
like
start
oseltamivir
de
novo
rvp
neg
result
howev
among
patient
start
therapi
test
fewer
half
prescrib
oseltamivir
confirm
influenza
viru
presum
physician
deem
delay
long
patient
benefit
associ
rvp
posit
deescal
antibiot
smaller
magnitud
patient
start
antibiot
test
subsequ
found
test
posit
influenza
viru
roughli
time
like
antibiot
discontinu
compar
test
neg
associ
statist
signific
adjust
potenti
confound
age
comorbid
variabl
significantli
correl
continu
antibiot
start
test
radiograph
suspicion
pneumonia
despit
wellestablish
fact
chest
radiographi
find
reliabl
differenti
bacteri
viral
lower
respiratori
tract
infect
even
infecti
noninfecti
ill
clinician
appear
influenc
radiograph
find
viral
test
result
make
antibiot
manag
decis
probabl
concern
bacteri
coinfect
true
patient
start
empir
therapi
presum
moresever
ill
presentationpati
treat
test
subsequ
found
posit
rvp
result
like
test
neg
virus
start
antibiot
within
first
day
agreement
data
retrospect
analys
canada
show
influenza
viru
posit
led
increas
use
antivir
test
result
correl
overal
antibiot
use
also
european
studi
found
associ
test
result
antibiot
use
overal
cost
find
import
implic
antimicrobi
stewardship
program
adult
acut
care
hospit
mere
provid
access
rapid
multiplex
test
may
suffici
reduc
antibiot
use
even
winter
influenza
viru
viral
pathogen
frequent
abil
interpret
posit
result
context
clinic
ill
legitim
concern
bacteri
coinfect
need
address
propos
use
procalcitoninguid
algorithm
predict
bacteri
infect
approach
yet
gain
wide
accept
recent
random
control
trial
evalu
algorithm
combin
procalcitonin
measur
viral
test
note
trend
toward
decreas
durat
antibiot
subgroup
lowest
risk
bacteri
infect
suggest
physician
respond
combin
viral
biomark
data
howev
studi
exclud
patient
radiograph
suspicion
pneumonia
make
difficult
extrapol
conclus
popul
data
also
question
pertin
panel
target
broad
array
respiratori
virus
hospit
patient
abil
detect
wide
rang
virus
might
critic
immunocompromis
patient
test
virus
commonli
link
lower
respiratori
tract
infect
ie
influenza
viru
rsv
possibl
adenoviru
metapneumoviru
might
costeffect
suffici
purpos
antimicrobi
stewardship
virus
typic
associ
upper
tract
infect
eg
rhinovirusenteroviru
parainfluenza
viru
inde
common
children
ambulatori
adult
detect
potenti
use
determin
viral
etiolog
asthmacopd
exacerb
howev
less
frequent
implic
hospit
adult
physician
legitim
difficulti
interpret
signific
detect
clinic
specimen
studi
limit
first
use
prospect
nonrandom
design
option
compar
impact
chang
manag
follow
avail
test
result
situat
test
avail
design
shown
valid
diagnost
test
evalu
use
care
defin
select
criteria
adjust
confound
variabl
limit
bias
second
restrict
analysi
antimicrobi
use
first
day
test
object
assess
immedi
chang
attribut
test
result
possibl
antimicrobi
use
cours
hospit
would
lower
among
patient
posit
rvp
find
equal
like
antibiot
would
given
addit
indic
nosocomi
infect
third
analyz
microbiolog
data
possibl
case
treat
confirm
bacteri
infect
howev
result
microbiolog
test
ie
cultur
blood
sputum
specimen
gener
final
sever
day
unlik
factor
much
clinician
earli
antimicrobi
manag
decis
final
sampl
size
virusposit
patient
popul
rel
small
make
difficult
draw
definit
conclus
specif
patient
outcom
viru
although
prospect
tri
identifi
patient
test
rvp
patient
influenza
may
like
includ
even
select
bia
occur
effect
influenza
viru
posit
antibiot
manag
small
make
unlik
bia
impact
conclus
significantli
conclus
multiplex
test
enabl
better
understand
burden
virus
respiratori
tract
infect
among
adult
influenza
viru
posit
associ
shorter
durat
hospit
lead
appropri
manag
decis
includ
institut
antivir
trend
toward
antibiot
deescal
howev
rapid
test
broad
array
virus
appear
use
stewardship
intervent
among
hospit
adult
patient
unless
combin
addit
mean
rule
bacteri
coinfect
supplementari
materi
avail
journal
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
